Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations (RAPAMALYMPH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03243019
Recruitment Status : Recruiting
First Posted : August 8, 2017
Last Update Posted : October 16, 2019
Ministry of Health, France
Information provided by (Responsible Party):
University Hospital, Lille

Brief Summary:

To evaluate the efficacy of Rapamycin in extended cervicofacial lymphatic malformations in pediatric patients. Rapamycin is administered oral for a 6 month period.

The success rate is determined by volume reduction superior to 1/5e of the initial volume measured by MRI, impact on QOL and reduction of bleeding in case of mucosal involvement.

Condition or disease Intervention/treatment Phase
Lymphatic Malformation Pediatric Drug: rapamycin Device: MRI Biological: Rapamycin dosage Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 28 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations of Poor Prognosis
Actual Study Start Date : June 25, 2018
Estimated Primary Completion Date : February 2022
Estimated Study Completion Date : February 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: SIROLIMUS Drug: rapamycin
oral administration

Device: MRI
cervicofacial MRI

Biological: Rapamycin dosage
Biological dosage of Rapamycin level

Primary Outcome Measures :
  1. Response rate to rapamycin [ Time Frame: At 3 months ]
    Volumetric assessment by MRI. A response is considered as positive if volume decrease is superior to 1/5th of the initial volume.

Secondary Outcome Measures :
  1. Kinetic of rapamycin response [ Time Frame: At 3, 6 and 12 months ]
    MRI assessment of the volume

  2. Efficacy of rapamycin on clinical symptoms [ Time Frame: At 3, 6 and 12 months ]
    Clinical and fiberscopy evaluation by scoring

  3. Pediatric Quality of Life Inventory (PedsQL 4) Scales [ Time Frame: Baseline, at 3, 6 and 12 months ]
    Assesses health-related quality of life among children with chronic and acute diseases

  4. Biological response to rapamycin [ Time Frame: Baseline and at 6 months ]
    biological effect of mTOR blockage by measuring pAKT, p70S6 kinase, pMEK, and VEGF C, VEGFR3

  5. Rapamycin side effects [ Time Frame: Monthly during 1 years ]
    Side effect assessment using the NCI-CTC 3.0 scale

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Year to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient from 1 to 18 years of age, presenting with poly-cystic suprahyoid or mediastinal lymphatic.
  • with chronic pain or functional respiratory or swallowing impairment with a CDS score < 8
  • Curative treatment is not possible or associated with a high risk of morbidity ,mortality and functional and cosmetic impairment
  • Karnofsky Score (> 10 years of age) or Lansky score (≤10 years of age) > 50%
  • Biology

    • Neutrophils count≥1.0 x 109/L
    • Platelets count ≥ 100 x 109/L
    • Hemoglobin ≥ 8 g/dL
    • Bilirubin ≤ 1,5 ULN
    • Transaminases < 2,5 ULN
    • Serum albumin ≥ 2 g/dL.
    • LDL cholesterol <160 mg/dL
    • Triglycerides < 150 mg/dL
  • Negative test of pregnancy if relevant
  • Social security affiliation
  • At least 2 months after a previous procedure on the malformation

Exclusion Criteria:

  • Non-respect of inclusion criteria
  • concomitant immuno-suppressor treatment
  • renal failure
  • Liver failure
  • Digestive disease leading to rapamycin malabsorption
  • uncontrolled or severe infectious disease
  • Patients requiring treatment interfering with CYP3A4 isoenzyme (rifampicin, rifabutin, carbamazepine, phenobarbital, phenytoin) or inhibiting CYP3A4 isoenzyme's activity (ketoconazole, voriconazole, itraconazole, telithromycin, clarithromycin, Diltiazem, Verapamil, nicardipine, clotrimazole, fluconazole , troleandomycin, bromocriptine, cimetidine, danazol, protease inhibitors) -patients requiring treatment by cisapride and metoclopramide
  • Concomitant administration of mTOR inhibitor
  • Peanuts or soya allergy
  • Impossibility to receive informed consent
  • Absence of social security affiliation
  • refusal to sign consent
  • Ongoing pregnancy or breastfeeding
  • refusal to participate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03243019

Layout table for location contacts
Contact: Pierre Fayoux, MD 3 20 44 50 67 ext +33

Layout table for location information
Hôpital Jeanne de Flandres, CHU Recruiting
Lille, France
Principal Investigator: pierre Fayoux, MD         
Sponsors and Collaborators
University Hospital, Lille
Ministry of Health, France
Layout table for investigator information
Principal Investigator: Pierre Fayoux, MD University Hospital, Lille

Layout table for additonal information
Responsible Party: University Hospital, Lille Identifier: NCT03243019    
Other Study ID Numbers: 2012_67
2013-002800-15 ( EudraCT Number )
First Posted: August 8, 2017    Key Record Dates
Last Update Posted: October 16, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Lille:
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphatic Abnormalities
Congenital Abnormalities
Lymphatic Vessel Tumors
Neoplasms by Histologic Type
Lymphatic Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs